Aethon therapeutics The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors.The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors.Jan 9, 2023 · ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells Jan 9, 2026 · Today, Aethon Therapeutics launches to create novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill persistent cancer cells. New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... anders holch povlsen Jan 9, 2026 · Aethon's HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy $30M in Series A funding, with $25M from Apple ... Jan 9, 2026 · ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells by PRNewswire January 9, 2026 7:00 AM | 6 min read Aethon's HapImmune™ platform, described in a... Nov 16, 2025 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures.ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells ...Aethon Therapeutics engineers novel antibodies, customized to be used in combination with targeted therapies to selectively kill drug-resistant cancer cells. Learn … everest m market Private Company "Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations." Aethon - Autonomous Mobile Robots - Healthcare and Hospitality Welcome to the one-of-a-kind world of Aethon. Aethon autonomous mobile robots don’t just change movement, they change everything. Workers can do more. Healthcare professionals can care more. Hospitality guests can experience more.Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations. About My expertise is in antibody discovery, antibody evolution and engineering, and antibody conjugation technologies. I joined Aethon Therapeutics, Inc. (New York, NY) as Chief Technology... Jan 9, 2026 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... summit warehouse and logistics Aethon Therapeutics, New York, NY. We are thrilled to announce today the launch of Aethon Therapeutics. Aethon, an ATP (Apple Tree Partners) company, unites immune and targeted therapy to expand the power and promise of both approaches for fighting cancer. Uniquely anchored in the HapImmune™ platform stemming from the laboratories of Profs. Researchers from NYU Langone Health's Perlmutter Cancer Center – Shohei Koide, PhD and Benjamin G. Neel, MD, PhD – have co-founded Aethon Therapeutics with Apple Tree Partners (ATP), a life sciences venture capital firm, to create novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill persistent cancer cells.Aethon Therapeutics, Inc. is a platform that is aimed at bridging the gap between targeted and immune therapy.Aethon Therapeutics Biotechnology Research New York, NY 451 followers Creating neoantigens by design -- to transform cancer treatments into cures Follow View all 3 employees About us Aethon...NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to …NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to develop cancer drugs that can overcome therapeutic resistance. Aethon launched with $30 million in Series A financing, $25 million of which comes from ATP.Jan 19, 2023 · Oncology On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics. Aethon recently launched January 9th, with... Feb 1, 2026 · Aethon - Autonomous Mobile Robots - Healthcare and Hospitality Welcome to the one-of-a-kind world of Aethon. Aethon autonomous mobile robots don’t just change movement, they change everything. Workers can do more. Healthcare professionals can care more. Hospitality guests can experience more. Aethon Therapeutics Inc. closed a $30 million series A round to develop a novel antibody-based therapeutic strategy for cancer, which relies on the concomitant use of small-molecule covalent inhibitors that form peptide-drug conjugates or beacons. Read More BioWorld Premium deily New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ...Please enter a search term. Primary Menu. News. Chicago News; Your Local Election HQ; Coronavirus; TrafficBenjamin G. Neel, M.D., Ph.D. – inventors of the HapImmune™ immunotherapy platform that is Aethon's drug discovery engine. Aethon is funded with $30 million in Series A financing, $25 million of which comes from ATP. NYU Langone Health also participated in this funding round and holds equity in Aethon.Researchers from NYU Langone Health's Perlmutter Cancer Center – Shohei Koide, PhD and Benjamin G. Neel, MD, PhD – have co-founded Aethon Therapeutics with Apple …Jan 9, 2023 · Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy. vingage About My expertise is in antibody discovery, antibody evolution and engineering, and antibody conjugation technologies. I joined Aethon Therapeutics, Inc. (New York, NY) as Chief Technology... AETHON THERAPEUTICS, INC. in Albany, NY | Company Info & Reviews Company Information Sponsored Links Company Contacts This company has not listed any contacts yet. Reviews Write Review There are no reviews yet for this company. Questions Post Question There are no questions yet for this company. ADDITIONAL LINKS Post …Jan 9, 2023 · NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to develop cancer drugs that can overcome therapeutic resistance. Aethon launched with $30 million in Series A financing, $25 million of which comes from ATP. Nov 16, 2025 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Oncology On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics. Aethon recently launched January 9th, with...Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy.Aethon Therapeutics Biotechnology Research New York, NY 451 followers Creating neoantigens by design -- to transform cancer treatments into cures Follow View all 3 employees About us Aethon... turnspire capital Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations. NYU Langone Health Researchers Launch Aethon Therapeutics with Venture Capital Firm. Appl Rad Oncol. By News Release | January 09, 2026 Categories: Technologies | Section About the Author News ReleaseJan 9, 2023 · Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy. Aethon Therapeutics Biotechnology Research New York, NY 451 followers Creating neoantigens by design -- to transform cancer treatments into cures Follow View all 3 employees About us Aethon...Nov 16, 2022 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations.Nov 16, 2022 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ...New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ...Feb 1, 2023 · Aethon Changes Health Care. Aethon mobile robots perform delivery and transportation tasks in hospitals to give staff more time to focus on patient care. Secure delivery of pharmacy medications and laboratory specimens and heavier loads such as meals, linens, and environmental services are all moved autonomously. NYU Langone Health Researchers Launch Aethon Therapeutics with Venture Capital Firm. Appl Rad Oncol. By News Release | January 09, 2026 Categories: Technologies | Section About the Author News Release sceye incfolk sam Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy.Researchers from NYU Langone Health's Perlmutter Cancer Center – Shohei Koide, PhD and Benjamin G. Neel, MD, PhD – have co-founded Aethon Therapeutics with Apple Tree Partners (ATP), a life sciences venture capital firm, to create novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill persistent cancer cells. beameryThe biotech company Aethon Therapeutics has launched in New York to develop antibody immunotherapies for tumors that have developed resistance to current …Jan 9, 2023 · ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells ... Aethon Therapeutics; Apertor Pharmaceuticals; Deep Apple Therapeutics; Neena Kadaba, an entrepreneur in residence at ATP, is a science-driven investor with 15 years of experience building novel collaborations and partnerships to drive innovation. Most recently, Neena was a Director at Quark Venture, where she served on the board of Eyevensys, …Jan 9, 2023 · Mohegan Sun begins spring fever with home and garden … 13 hours ago Dr. Neel co-developed the technology with Shohei Koide, PhD, and it is now being commercialized by Aethon Therapeutics in partnership with NYU Langone. Building on Decades of Research Physician Focus: Dr. Neel, you’ve been involved in the advancement of translational programs in immunotherapy, cancer genetics, and targeted therapies for ... harri com Aethon Therapeutics Biotechnology Research New York, NY 451 followers Creating neoantigens by design -- to transform cancer treatments into cures Follow View all 3 employees About us Aethon...Plus: Boehringer, 3T partner to discover new TCR targets and updates from Immunocore, Ionis-Royalty, Kronos, Genentech, ATP’s AethonMohegan Sun begins spring fever with home and garden … 13 hours agoBioWorld Financial Watch — Aethon $30M series A round targets drug-based neoantigens. News • Jan 9, 2023. BioSpace — ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells.Private Company "Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations."Jan 9, 2023 · Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy. About Aethon Therapeutics. Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. Aethon’s novel anti-drug ... Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures.Aethon Therapeutics, New York, NY. We are thrilled to announce today the launch of Aethon Therapeutics. Aethon, an ATP (Apple Tree Partners) company, unites immune and targeted therapy to expand the power and promise of both approaches for fighting cancer. Uniquely anchored in the HapImmune™ platform stemming from the laboratories of Profs. sigma biPOSITION SUMMARY We are seeking an ambitious, curious, and passionate Associate Scientist to join Aethon’s dynamic research team with expertise in molecular biology, immunology, and in vitro...Jan 9, 2023 · Powerful quake rocks Turkey and Syria, killing more … 36 mins ago Jan 9, 2026 · The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors. Jan 9, 2026 · Please enter a search term. Primary Menu. Billings Beat. Billings Beat News with Mary Beth Dickson; Animal Bites with Jeff the Nature Guy Today, Aethon Therapeutics begins developing novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill stubborn cancer cells. Apple Tree Partners (ATP), a leading provider of life sciences venture capital, formed Aethon with researchers at NYU Langone Health’s Perlmutter Cancer Center – Shohei …Please enter a search term. Primary Menu. News. Chicago News; Your Local Election HQ; Coronavirus; Traffic dash financial Jan 9, 2026 · Powerful quake rocks Turkey and Syria, killing more … 36 mins ago We're working on getting contact data for Aethon Therapeutics . Find more contact data in Search! Get started . Board Member and Advisor Profiles. Edit Board Member and Advisor Profiles Section. Number of Board Member and Advisor Profiles 1. Aethon Therapeutics has 1 board member or advisor, Seth Harrison. Seth Harrison Board Member 2023. …Aethon Therapeutics has raised a total of $30M in funding over 1 round. This was a Series A round raised on Jan 9, 2023. Aethon Therapeutics is funded by 2 …Associate Scientist Aethon Therapeutics New York, NY 1 month ago Be among the first 25 applicants See who Aethon Therapeutics has hired for this role No longer accepting applications WHO WE ARE...Jan 9, 2023 · ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells ... Jan 9, 2026 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... Jan 9, 2026 · Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. Explore Aethon Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news. Get 7 Days Free Sign In Sign In TopicsNEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to …Jan 9, 2023 · Mohegan Sun begins spring fever with home and garden … 13 hours ago The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either ... Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations.Please enter a search term. Primary Menu. Watch Live 📺; News. Local News; California; National & World News; EntertainmentBenjamin G. Neel, M.D., Ph.D. – inventors of the HapImmune™ immunotherapy platform that is Aethon's drug discovery engine. Aethon is funded with $30 million in Series A financing, $25 million of which comes from ATP. NYU Langone Health also participated in this funding round and holds equity in Aethon. corridor capital About Aethon Therapeutics. Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. Aethon’s novel anti-drug ...Aethon Therapeutics engineers novel antibodies, customized to be used in combination with targeted therapies to selectively kill drug-resistant cancer cells. Learn …Jan 9, 2023 · Powerful quake rocks Turkey and Syria, killing more … 36 mins ago gorooofertasimpleutility holding llcAssociate Scientist Aethon Therapeutics New York, NY 1 month ago Be among the first 25 applicants See who Aethon Therapeutics has hired for this role No longer accepting applications WHO WE ARE...Jan 9, 2023 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... Jan 9, 2026 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... expressions llc Jan 9, 2026 · 9 January 2026 Aethon’s HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy $30M in Series A funding, with $25M from Apple Tree Partners (ATP) and participation by NYU Langone Health Researchers from NYU Langone Health's Perlmutter Cancer Center – Shohei Koide, PhD and Benjamin G. Neel, MD, PhD – have co-founded Aethon Therapeutics with Apple Tree Partners (ATP), a life sciences venture capital firm, to create novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill persistent cancer cells. NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to develop cancer drugs that can overcome therapeutic resistance. Aethon launched with $30 million in Series A financing, $25 million of which comes from ATP.Dr. Neel co-developed the technology with Shohei Koide, PhD, and it is now being commercialized by Aethon Therapeutics in partnership with NYU Langone. Building on Decades of Research Physician Focus: Dr. Neel, you’ve been involved in the advancement of translational programs in immunotherapy, cancer genetics, and targeted therapies for ... a new direction credit union Jan 9, 2026 · Please enter a search term. Primary Menu. News. Chicago News; Your Local Election HQ; Coronavirus; Traffic Jan 9, 2026 · The biotech company Aethon Therapeutics has launched in New York to develop antibody immunotherapies for tumors that have developed resistance to current cancer drugs. The company is funding its work with a $30 million Series A round. Aethon is the result of an alliance between the life sciences venture capital firm ATP and a research team from ... The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors. smart commerce Get 7 Days Free Sign In Sign In TopicsCombating Cancer and Infectious Diseases with Immunotherapeutic Technologies. Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and ... The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors.Jan 9, 2023 · Get 7 Days Free Sign In Sign In Topics bright mountain mediadamien kieranBenjamin G. Neel, M.D., Ph.D. – inventors of the HapImmune™ immunotherapy platform that is Aethon's drug discovery engine. Aethon is funded with $30 million in Series A financing, $25 million of which comes from ATP. NYU Langone Health also participated in this funding round and holds equity in Aethon. Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. wing alpha Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures.Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy.Private Company "Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations." The biotech company Aethon Therapeutics has launched in New York to develop antibody immunotherapies for tumors that have developed resistance to current … prestigepeo Aethon $30M series A round targets drug-based neoantigens. Jan. 9, 2023. By Cormac Sheridan. Aethon Therapeutics Inc. closed a $30 million series A round to …Nov 16, 2022 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Aethon, an ATP (Apple Tree Partners) company, unites immune and targeted therapy to expand the power and promise of both approaches for fighting cancer. Uniquely anchored in the HapImmune ... salisbury door and hardware Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations. Jan 9, 2026 · Please enter a search term. Primary Menu. News. Chicago News; Your Local Election HQ; Coronavirus; Traffic NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to develop cancer drugs that can overcome therapeutic resistance. Aethon launched with $30 million in Series A financing, $25 million of which comes from ATP.Plus: Boehringer, 3T partner to discover new TCR targets and updates from Immunocore, Ionis-Royalty, Kronos, Genentech, ATP’s Aethon jellco container Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations. Jan 9, 2026 · Today, Aethon Therapeutics begins developing novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill stubborn cancer cells. Apple Tree Partners (ATP), a leading provider of life sciences venture capital, formed Aethon with researchers at NYU Langone Health’s Perlmutter Cancer Center – Shohei ... About My expertise is in antibody discovery, antibody evolution and engineering, and antibody conjugation technologies. I joined Aethon Therapeutics, Inc. (New York, NY) as Chief Technology...Aethon Therapeutics, New York, NY. We are thrilled to announce today the launch of Aethon Therapeutics. Aethon, an ATP (Apple Tree Partners) company, unites immune and targeted therapy to expand the power and promise of both approaches for fighting cancer. Uniquely anchored in the HapImmune™ platform stemming from the laboratories of Profs. New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... excel utility contractors Jan 9, 2026 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... B.G.N. is the co-founder, hold equity and receive consulting revenue from Aethon Therapeutics. A.N.H. has received research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Nuvalent, Pfizer, Roche/Genentech, Scorpion Therapeutics; has served as a compensated consultant for …Aethon Therapeutics, Inc. is a platform that is aimed at bridging the gap between targeted and immune therapy.Jan 9, 2023 · The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors. vt capital Please enter a search term. Primary Menu. News. KNWA; FOX24; Around Arkansas; Around the Region; Black History MonthAbout My expertise is in antibody discovery, antibody evolution and engineering, and antibody conjugation technologies. I joined Aethon Therapeutics, Inc. (New York, NY) as Chief Technology... medical informatics corpviecureJan 9, 2026 · NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to develop cancer drugs that can overcome therapeutic resistance. Aethon launched with $30 million in Series A financing, $25 million of which comes from ATP. Aethon's HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy $30M in Series A funding, with $25M from Apple ...Please enter a search term. Primary Menu. Watch Live 📺; News. Local News; California; National & World News; Entertainment trugreen limited partnership Aethon Changes Health Care. Aethon mobile robots perform delivery and transportation tasks in hospitals to give staff more time to focus on patient care. Secure delivery of pharmacy medications and laboratory specimens and heavier loads such as meals, linens, and environmental services are all moved autonomously. unluOncology On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics. Aethon recently launched January 9th, with...Aethon Therapeutics, New York, NY. We are thrilled to announce today the launch of Aethon Therapeutics. Aethon, an ATP (Apple Tree Partners) company, unites immune and targeted therapy to expand the power and promise of both approaches for fighting cancer. Uniquely anchored in the HapImmune™ platform stemming from the laboratories of Profs. Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations.Benjamin G. Neel, M.D., Ph.D. – inventors of the HapImmune™ immunotherapy platform that is Aethon's drug discovery engine. Aethon is funded with $30 million in Series A financing, $25 million of which comes from ATP. NYU Langone Health also participated in this funding round and holds equity in Aethon. quinn city of industry Jan 9, 2026 · ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells Jan 9, 2026 · ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells by PRNewswire January 9, 2026 7:00 AM | 6 min read Aethon's HapImmune™ platform, described in a... Jan 9, 2026 · Aethon Therapeutics engineers novel antibodies, customized to be used in combination with targeted therapies to selectively kill drug-resistant cancer cells. ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE SCIENCES COMPANIES. Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. draslovka Please enter a search term. Primary Menu. Watch Live 📺; News. Local News; California; National & World News; EntertainmentThe Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either ... Jan 9, 2026 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... Jan 9, 2026 · Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy. boston gene The firm, founded by NYU Langone Health's Perlmutter Cancer Center researchers and Apple Tree Partners, will initially focus on studying antibodies combined with KRAS and EGFR inhibitors.Aethon's HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy $30M in Series A...Nearly five-hour meeting ends with big Urbana School … 22 mins ago gas n grub Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies, engineered using the company’s proprietary HapImmune™ platform, are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other …Jan 19, 2023 · Oncology On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics. Aethon recently launched January 9th, with... Jan 9, 2026 · Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy. tulsa manufacturing companies Jan 9, 2026 · Get 7 Days Free Sign In Sign In Topics About My expertise is in antibody discovery, antibody evolution and engineering, and antibody conjugation technologies. I joined Aethon …Aethon Therapeutics New York, NY 2 weeks ago Be among the first 25 applicants See who Aethon Therapeutics has hired for this role No longer accepting applications WHO WE ARE Aethon... oscar renda contractingMohegan Sun begins spring fever with home and garden … 13 hours agoNew therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ...Nov 16, 2022 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. paul w markstemplafyAbout Aethon Therapeutics. Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. Aethon’s novel anti-drug ... Mohegan Sun begins spring fever with home and garden … 13 hours agoJan 9, 2023 · Please enter a search term. Primary Menu. Watch Live 📺; News. Local News; California; National & World News; Entertainment Nov 16, 2025 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Get 7 Days Free Sign In Sign In Topics data clymer Private Company "Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations." Jan 9, 2026 · New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop ... ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells ...Aethon Therapeutics Overview Update this profile Founded 2022 Status Private Latest Deal Type Series A Latest Deal Amount $30M Investors 2 General Information Description Operator of a health technology platform intended to serve the convergence of targeted and immune therapy.NYU Langone Health Researchers Launch Aethon Therapeutics with Venture Capital Firm. Appl Rad Oncol. By News Release | January 09, 2026 Categories: Technologies | Section About the Author News Release NEW YORK – Researchers from NYU Langone Health's Perlmutter Cancer Center and Apple Tree Partners (ATP) on Monday launched Aethon Therapeutics to …Nov 16, 2022 · Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Jan 19, 2026 · Oncology On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics. Aethon recently launched January 9th, with... Aethon Therapeutics unites immunotherapy and targeted therapy, to expand the power and promise of both approaches for fighting cancer. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other cancer-associated mutations.